IDXX

IDXX

USD

IDEXX Laboratories Inc. Common Stock

$722.120+4.680 (0.652%)

Prix en Temps Réel

Healthcare
Diagnostics & Research
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$717.440

Haut

$726.500

Bas

$707.755

Volume

0.58M

Fondamentaux de l'Entreprise

Capitalisation Boursière

57.8B

Industrie

Diagnostics & Research

Pays

United States

Statistiques de Trading

Volume Moyen

0.48M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $356.14Actuel $722.120Haut $735

Rapport d'Analyse IA

Dernière mise à jour: 3 nov. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

IDEXX (IDXX) on the Launchpad? A Fresh Upgrade Could Fuel the Next Big Move

Generated: November 03, 2025, 10:05 AM EDT

The Headline That Changed Everything

The story for IDEXX Laboratories right now boils down to one powerful piece of news. On the last day of October, analysts at Stifel didn't just nudge their rating; they upgraded the stock from Hold to Buy. More importantly, they boosted their price target to a hefty $700. This isn't just noise. A move this decisive from a respected firm often forces the market to pay attention, acting as a strong catalyst that can shift investor sentiment almost overnight. The data shows this news is viewed as overwhelmingly positive, and it's the central force driving the current conversation around the stock.

A Volatile Past Sets a Tense Stage

Looking at the stock chart tells a story of explosive energy followed by a long period of consolidation. Back on August 4th, the stock absolutely rocketed from the $530s to over $680 in a single session on massive volume. That move set a new high-water mark for the year. Ever since that peak, the stock has been digesting the huge gain, trading mostly in a wide range between the low $620s and the mid $660s.

This recent history is critical. The stock has pulled back from its highs and is now hovering just above a support level around $628. After months of sideways action, the price is coiled. The arrival of a major analyst upgrade at this specific technical juncture is what makes the current situation so compelling. The stage is set for a potential breakout.

When the Machines Agree with Wall Street

The algorithmic forecast adds another layer of conviction to the bullish short-term picture. The AI model is not fighting the trend; it's leaning into it. It projects a string of positive days ahead:

  • Day 1: +3.13%
  • Day 2: +2.35%
  • Day 3: +4.40%

This isn't just a vague prediction. The system shows high confidence and projects a move toward a target price of $669.81. When a major analyst upgrade, a tense technical setup, and a confident AI forecast all point in the same direction, it creates a powerful argument for a near-term move higher. The data suggests the recent buying pressure is extremely strong, with trading volume surging well beyond its average.

The Bottom Line

The evidence points toward a short-term trading opportunity in IDEXX, driven by the powerful catalyst of the Stifel upgrade. While the company's fundamentals raise long-term questions--specifically its high valuation (P/E of 52.6) and debt levels--the immediate momentum appears to be strongly positive. This is a play on sentiment and technicals, not a classic value investment.

For traders aligned with a short-term horizon (1-2 weeks), the data suggests a specific strategy:

  • Potential Entry Zone: The analysis identifies a tight cluster of entry points between $629.95 and $632.23.
  • Profit Target: A disciplined exit could be considered around $641.13.
  • Risk Management: A stop-loss order near $565.70 is suggested to protect against a sharp reversal.

This setup is built on the idea that the recent positive news will provide enough fuel to break the stock out of its recent range.


Disclaimer: This report is for informational purposes only and is not intended as investment advice. The analysis is based exclusively on the structured data provided and does not constitute a recommendation to buy or sell any security. All investments involve risk, and you should conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.

Actualités Connexes

Analyst Upgrades

Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $805

Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories with a Overweight and raises the price target from $765 to $805.

Voir plus
Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $805
Analyst Upgrades

UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $750

UBS analyst Andrea Alfonso maintains IDEXX Laboratories with a Neutral and raises the price target from $710 to $750.

Voir plus
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $750
Analyst Upgrades

JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $775

JP Morgan analyst Chris Schott maintains IDEXX Laboratories with a Overweight and raises the price target from $675 to $775.

Voir plus
JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $775
Analyst Upgrades

BTIG Maintains Buy on IDEXX Laboratories, Raises Price Target to $830

BTIG analyst Mark Massaro maintains IDEXX Laboratories with a Buy and raises the price target from $785 to $830.

Voir plus
BTIG Maintains Buy on IDEXX Laboratories, Raises Price Target to $830
Reuters

S&P 500, Nasdaq gain after Amazon-OpenAI deal; Kenvue soars after buyout

The S&P 500 and Nasdaq kicked off November on firmer ground on Monday, after a slew of AI deals boosted megacap companies Amazon and Nvidia, while Kenvue shares soared after Kimberly-Clark's buyout deal.

Voir plus
S&P 500, Nasdaq gain after Amazon-OpenAI deal; Kenvue soars after buyout
Analyst Upgrades

Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook

Idexx stock gains after Q3 earnings and revenue beat expectations, driven by strong CAG growth and raised 2025 earnings and sales guidance.

BusinessWire

IDEXX Laboratories Announces Third Quarter Results

Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic revenue growth was supported by IDEXX

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 4 nov. 2025, 20:22

BaissierNeutreHaussier

69.1% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
Conservateur
Guide de Trading

Point d'Entrée

$634.04

Prise de Bénéfices

$643.73

Stop Loss

$568.00

Facteurs Clés

Le DMI montre une tendance baissière (ADX:18.7, +DI:7.3, -DI:9.7), suggérant la prudence
Le volume de transactions est 14.9x la moyenne (4,744), indiquant une pression d'achat extrêmement forte
Le MACD -0.0464 est au-dessus de la ligne de signal -0.3913, indiquant un croisement haussier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.